Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy

The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and “antibody interference” might hinder immune responses leading to vaccine failure. In an institutional review board–approved prospective study, we found that an indivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz-Cherry, Stacey, McGargill, Maureen A, Thomas, Paul G, Estepp, Jeremie H, Gaur, Aditya H, Allen, E Kaitlynn, Allison, Kim J, Tang, Li, Webby, Richard J, Cherry, Sean D, Lin, Chun-Yang, Fabrizio, Thomas, Tuomanen, Elaine I, Wolf, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454518/
https://www.ncbi.nlm.nih.gov/pubmed/34557558
http://dx.doi.org/10.1093/ofid/ofab420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454518/
https://www.ncbi.nlm.nih.gov/pubmed/34557558
http://dx.doi.org/10.1093/ofid/ofab420

Ejemplares similares